BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235) has reported new Phase 1 clinical findings from three investigational oncology medicines targeting advanced hepatocellular carcinoma and non-small cell lung cancer, as the company accelerates development of its solid tumor pipeline. Disclosed at the European Society for Medical Oncology Congress 2026 in Madrid on October 24, the results cover the GPC3 and 4-1BB bispecific antibody BGB-B2033, the brain-penetrant PRMT5 inhibitor BGB-58067 and the CEA-targeting antibody-drug conjugate BG-C477.
The programmes represent three distinct approaches to treating difficult cancers. BGB-B2033 seeks to concentrate T-cell activation within glypican-3-expressing liver tumors, BGB-58067 exploits a molecular vulnerability associated with MTAP deficiency, and BG-C477 delivers a cytotoxic payload to cancer cells expressing carcinoembryonic antigen-related cell adhesion molecule 5.
The data show signs of antitumor activity in heavily pretreated populations, including patients with prior immune checkpoint inhibitor exposure, molecularly selected lung cancers and brain metastases. However, the evidence comes from early-stage, predominantly uncontrolled studies, and the results cannot establish superiority over currently available treatments. Their commercial significance will depend on whether BeOne can reproduce the findings in larger studies while maintaining acceptable safety profiles.
BeOne plans to initiate registrational development of BGB-B2033 in previously treated hepatocellular carcinoma by the end of 2026 and intends to advance its two lung cancer programmes toward later-stage development in 2027. These timelines reflect management plans rather than completed clinical milestones.
What do the latest BGB-B2033 results reveal about GPC3-targeted treatment for advanced liver cancer?
BGB-B2033 is an investigational bispecific antibody designed to bind glypican-3, or GPC3, and the immune costimulatory receptor 4-1BB. Glypican-3 is frequently expressed in hepatocellular carcinoma, while 4-1BB participates in T-cell activation. The therapeutic hypothesis is that binding both targets can concentrate immune stimulation near cancer cells while limiting systemic activation.
The updated Phase 1 study involved dose-escalation and dose-optimization cohorts of patients with advanced hepatocellular carcinoma who had received previous systemic treatment. According to BeOne’s October announcement, 94 patients were included in the reported analysis, of whom 93.6% had previously received PD-1 or PD-L1-directed therapy. Approximately 61.7% had received both checkpoint inhibition and a tyrosine kinase inhibitor.
The company highlighted a confirmed objective response rate of 36% at what it described as its selected Phase 3 dose of 450 milligrams every three weeks. It also reported an estimated six-month duration-of-response rate of 74.1% at that selected dose, indicating that a substantial proportion of responding patients maintained their responses at the six-month assessment.
However, the accompanying ESMO scientific summary provides a materially different response estimate for the 450-milligram dose-optimization cohort. That analysis, using an April 26, 2026 data cutoff, reported five confirmed responses among 23 evaluable patients, corresponding to 21.7%. The same scientific summary identified a 35.7% response rate at 600 milligrams in a separate dose-escalation cohort of 14 patients.
The published materials do not reconcile the corporate announcement’s 36% figure with the dose-specific scientific results. The numbers therefore cannot be treated as interchangeable estimates of response in the same 450-milligram population. For clinical interpretation, the separately described dose cohorts provide a more transparent basis for evaluating the preliminary efficacy signal.
The scientific presentation also reported response rates of 28.6% at 300 milligrams and 20.0% at 1,000 milligrams within the dose-escalation cohorts. In the dose-optimization groups, the 900-milligram dose produced a 16.0% response rate. These findings illustrate why selection of an appropriate dose requires consideration of the full exposure, safety and efficacy profile rather than assuming that higher doses necessarily produce better outcomes.
The overall findings remain relevant because the study enrolled patients with limited remaining treatment options. Nevertheless, objective response in a single-arm early-stage study does not independently establish improved progression-free or overall survival.
Why could GPC3 and 4-1BB targeting offer a different approach after liver cancer immunotherapy?
Advanced hepatocellular carcinoma is increasingly treated with combinations involving immune checkpoint inhibitors, anti-angiogenic medicines and other systemic therapies. Despite these advances, many patients eventually experience progression and require additional treatment. The effectiveness and tolerability of subsequent therapies depend on previous treatment exposure, liver function and the underlying disease burden.
BGB-B2033 attempts to address this setting through tumor-associated activation of 4-1BB. Unlike conventional checkpoint inhibitors, which interfere with inhibitory immune signals, 4-1BB agonism aims to deliver a positive costimulatory signal to T cells. Concentrating that signal around GPC3-expressing tumors could potentially improve antitumor activity while reducing unwanted immune activation in normal tissues.
The distinction is clinically important because earlier systemic approaches to 4-1BB activation have faced safety and therapeutic-index challenges. Uncontrolled immune stimulation can potentially produce inflammatory toxicities, including liver injury. This is particularly relevant in hepatocellular carcinoma, where patients may already have impaired liver function because of cirrhosis or other underlying disease.
BeOne designed BGB-B2033 with reduced antibody-dependent cellular cytotoxicity and tumor-associated 4-1BB activation. These engineering characteristics are intended to reduce systemic toxicity, but preclinical design features alone cannot establish a favourable safety profile. Human clinical evidence remains necessary to determine whether the mechanism achieves sufficient tumor activity without unacceptable immune-mediated complications.
The reported Phase 1 safety findings were encouraging within the disclosed observation period. BeOne stated that Grade 3 or higher treatment-related adverse events occurred in approximately 5.3% of patients across evaluated doses, while treatment-related events led to discontinuation in 2.1%. The more detailed scientific summary reported Grade 3 treatment-related events in approximately 5% of enrolled patients, with no Grade 4 or 5 treatment-related events observed.
These results support continued evaluation, although larger trials will be necessary to characterise uncommon adverse events and longer-term effects. The clinical significance of the mechanism will ultimately depend on whether the candidate improves patient outcomes compared with established treatment options.
How close is BGB-B2033 to a pivotal hepatocellular carcinoma trial?
BeOne has selected 450 milligrams administered every three weeks for further development. Its Phase 1 programme was designed to assess safety, tolerability, pharmacokinetics and preliminary antitumor activity while informing dose selection. The identification of a development dose represents progress toward pivotal testing, but it is not proof that the selected regimen is optimal in every relevant patient population.
The company has received United States Food and Drug Administration Fast Track designation for BGB-B2033 in hepatocellular carcinoma, granted in December 2025. The medicine also received United States orphan drug designation in March 2026 and European Commission orphan designation in October 2026. These regulatory actions may provide development incentives or opportunities for closer regulatory interaction, but they do not establish efficacy or constitute marketing approval.
A planned randomised study will compare BGB-B2033 with investigator’s choice of sorafenib or lenvatinib in previously treated hepatocellular carcinoma. The registered study is designed to investigate clinical efficacy and safety in patients with prior exposure to PD-1 or PD-L1-directed treatment. Its comparator structure is relevant because it will permit direct evaluation against established systemic treatment options rather than relying on historical response-rate comparisons.
Such a study could provide stronger evidence about the candidate’s therapeutic contribution in patients whose disease has progressed despite immunotherapy. Endpoints addressing disease control, progression and survival will be important for establishing whether the early response signal translates into clinically meaningful benefit.
Execution will also require careful patient selection. Liver function, prior therapy and underlying cirrhosis can substantially affect treatment tolerability and outcomes in hepatocellular carcinoma. A pivotal trial will need to account for these variables when assessing both safety and efficacy.
What does BGB-58067’s PRMT5 inhibition reveal about treatment of MTAP-deficient lung cancer?
The second major programme involves BGB-58067, an investigational oral inhibitor of protein arginine methyltransferase 5, known as PRMT5. The medicine is designed to exploit a metabolic vulnerability created by deficiency of methylthioadenosine phosphorylase, or MTAP. This approach differs fundamentally from conventional chemotherapy because it seeks to identify cancer cells with a particular molecular characteristic that may increase their susceptibility to targeted enzyme inhibition.
Loss of MTAP can lead to accumulation of methylthioadenosine, which influences PRMT5-associated biological activity. BGB-58067 is designed to interact preferentially with PRMT5 in the presence of methylthioadenosine, potentially providing greater selectivity for MTAP-deficient tumor cells than traditional PRMT5 inhibition.
The October company disclosure described initial Phase 1 findings involving 182 patients with advanced MTAP-deficient tumors, including 83 with non-small cell lung cancer. Among 75 efficacy-evaluable lung cancer patients, the confirmed objective response rate was 25.3%, and the disease control rate reached 76.0%. Median progression-free survival was reported at 7.7 months in the overall lung cancer cohort.
The results were more favourable in the EGFR wild-type subgroup, where the confirmed response rate reached 38.5%, the disease control rate was 82.1% and median progression-free survival was 8.1 months. These differences may help identify populations for further investigation, although the subgroup findings do not establish that EGFR status independently predicts benefit from PRMT5 inhibition.
The study remains an early-stage investigation without a randomised control group. The observed progression-free survival outcomes therefore cannot be attributed to treatment efficacy with the same certainty available from a controlled comparison.
An additional scientific question concerns the relationship between MTAP deficiency and the broader molecular characteristics of lung cancer. Co-occurring genomic alterations and previous treatments may affect responsiveness to PRMT5 inhibition. Further biomarker analyses could help determine whether MTAP status alone is sufficient for patient selection or whether additional factors are clinically relevant.
Why is the 30.8% intracranial response rate important for BGB-58067?
One potentially distinctive feature of BGB-58067 is its intended ability to penetrate the central nervous system. Brain metastases are a substantial clinical challenge in advanced non-small cell lung cancer because therapeutic delivery across the blood-brain barrier can limit the effectiveness of some systemic medicines. A molecularly targeted treatment demonstrating meaningful intracranial activity could potentially address an important unmet need.
BeOne reported an intracranial objective response rate of 30.8% among patients with untreated, asymptomatic brain metastases. The finding suggests that the investigational medicine achieved antitumor activity within the central nervous system in a subset of treated patients. It provides preliminary clinical support for the brain-penetrant characteristics observed during preclinical development.
However, the company has not provided a complete numerical breakdown of intracranial response duration, central nervous system progression-free survival or the size of every relevant brain metastasis subgroup in the October announcement. These details will be important in determining how robust the signal is and whether responses are maintained over time.
The safety findings also require careful assessment. At daily doses ranging from 200 to 400 milligrams, Grade 3 or higher treatment-related adverse events occurred in 27.6% of 87 patients, while treatment-related adverse events led to discontinuation in 5.7%. Nausea, anemia and fatigue were among the commonly reported events.
The results indicate that significant treatment-related toxicity occurred in a meaningful proportion of patients, even within the dose range selected for continued evaluation. Longer exposure and larger studies will be necessary to determine whether the balance between antitumor activity and adverse effects remains acceptable.
BeOne intends to advance BGB-58067 toward later-stage clinical development in 2027. The next important evidence will involve larger biomarker-defined cohorts, more mature intracranial results and further evaluation of the relationship between drug exposure, response and toxicity.
Can BG-C477’s 56% response rate establish a new opportunity in CEA-high lung cancer?
The third programme involves BG-C477, an investigational antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5, also known as CEACAM5 or CEA. The molecule combines a CEA-directed antibody with a cleavable linker and a topoisomerase I inhibitor payload. Its design is intended to deliver cytotoxic activity preferentially to cancer cells expressing the target antigen.
BeOne reported preliminary Phase 1 monotherapy findings from 43 heavily pretreated patients with non-small cell lung cancer, including 25 with high tumor CEA expression. The confirmed objective response rate was 34.9% in the overall group and 56.0% among patients with high CEA expression. The disease control rate in the high-expression group reached 88.0%.
The more detailed scientific summary reported 14 confirmed partial responses among the 25 patients classified as having high CEA expression. In the lower-expression subgroup, the response rate was 5.6%, corresponding to one partial response among 18 patients. The difference provides a strong rationale for further evaluation of CEA expression as a potential predictive biomarker.
However, the study was not a randomised comparison between biomarker-defined treatment strategies. CEA expression was assessed retrospectively using central laboratory immunohistochemistry, and the findings do not independently validate a clinical companion diagnostic threshold. A larger programme will need to establish whether the observed relationship remains reproducible across different patient populations.
The median duration of response had not been reached at the April 9, 2026 data cutoff. The median study follow-up was approximately 4.2 months, indicating that response durability remained immature. The fact that several patients continued treatment is encouraging but does not establish long-term disease control.
The company reported Grade 3 or higher treatment-emergent adverse events in 44.2% of the 43 patients. These included anemia in 14.0%, neutropenia in 14.0% and thrombocytopenia in 2.3%. Two patients discontinued treatment because of treatment-emergent adverse events, while no treatment-related fatal adverse events were reported.
BG-C477 received FDA Fast Track designation in October 2026. The designation may facilitate development and regulatory communication, but the candidate remains investigational and has not established superiority over available lung cancer treatments.
Updated clinical results are scheduled for presentation on October 26, making the current findings an initial evidence package rather than the final ESMO disclosure.
How do the three mechanisms affect BeOne Medicines’ emerging solid tumor strategy?
The three programmes demonstrate a strategy based on using different therapeutic modalities to address specific aspects of tumor biology. BGB-B2033 involves localized immune costimulation, BGB-58067 exploits a genomic and metabolic vulnerability, and BG-C477 combines biomarker-directed antibody targeting with cytotoxic drug delivery. Their mechanisms, development populations and safety considerations are sufficiently different that success in one programme would not establish efficacy in the others.
For hepatocellular carcinoma, BeOne is targeting patients who have progressed after immunotherapy and may have limited subsequent treatment options. In non-small cell lung cancer, its programmes seek to identify molecular or antigen-defined populations where targeted therapies may provide additional benefit after conventional treatment. This approach places increasing importance on biomarker testing and appropriate patient selection.
The company already has an established solid tumor commercial presence through TEVIMBRA (tislelizumab), a PD-1-directed monoclonal antibody approved for specified indications across several markets. However, the three investigational medicines are separate assets and cannot be regarded as commercially available components of the TEVIMBRA portfolio.
BeOne is also advancing the selective CDK4 inhibitor BGB-43395 through the global Phase 3 KANDELA-302 trial in hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. That study began enrolling patients in May 2026 and evaluates BGB-43395 plus letrozole against investigator’s choice of an established CDK4/6 inhibitor plus letrozole.
The KANDELA-302 programme provides additional context for the company’s broader solid tumor ambitions but does not belong to the liver or lung cancer efficacy datasets. It represents a separate investigational programme with its own clinical and commercial development requirements.
The longer-term significance of BeOne’s strategy will depend on whether it can convert multiple early-stage scientific mechanisms into reproducible, clinically meaningful treatment benefits. Building a diversified oncology pipeline reduces dependence on one investigational hypothesis, but it also increases the importance of development prioritisation and disciplined trial execution.
What do BeOne’s financial performance and stock sentiment indicate about its ability to fund development?
BeOne’s financial position provides an important distinction from smaller biotechnology companies dependent primarily on external funding. For the second quarter of 2026, the company reported total revenue of approximately $1.7 billion, representing 30% growth from the previous year. Global revenue from BRUKINSA (zanubrutinib) reached approximately $1.2 billion, providing a substantial commercial foundation for research investment.
The company also reported quarterly generally accepted accounting principles net income of approximately $237 million and free cash flow of $435 million. These results indicate that its established commercial business is generating cash while the company advances new oncology programmes. BeOne increased its full-year 2026 revenue guidance to between $6.6 billion and $6.8 billion.
For an oncology developer with several potential late-stage programmes, this financial capacity may support parallel investment in clinical studies, manufacturing preparation and regulatory development. Nevertheless, the scale and timing of future investment will depend on trial designs, patient recruitment and the strength of emerging evidence.
BeOne’s Nasdaq-listed American depositary shares closed at $377.63 on October 23, 2026, down approximately 1.2% for the session but above their October 16 closing level of $369.06. The stock was trading near the upper end of its recent one-year range, reflecting the company’s broader commercial and pipeline expectations rather than a market reaction specifically to the October 24 clinical announcement.
The share-price performance should not be attributed to the latest ESMO results because the main announcement was issued after the October 23 regular trading session. Investors evaluating the company are likely to consider its established commercial earnings alongside future pipeline opportunities, but the three Phase 1 assets remain longer-term development prospects.
Which clinical milestones will determine whether BeOne’s early responses become meaningful therapies?
BGB-B2033 has the clearest near-term pivotal development objective, with BeOne targeting registrational trials in previously treated hepatocellular carcinoma by the end of 2026. The key requirement will be demonstrating that the bispecific antibody improves clinically meaningful outcomes compared with an active treatment control. More complete reconciliation of the dose-specific response data and continued safety evaluation will also be important.
For BGB-58067, further development will need to establish whether MTAP deficiency identifies a population with reproducible benefit and whether the reported intracranial activity remains meaningful with longer follow-up. The potential to treat brain metastases could become a differentiated characteristic, but only if supported by more mature central nervous system response and safety data.
BG-C477 will require additional investigation of CEA expression thresholds, response durability and cytotoxic toxicity. The apparent separation between high- and low-expression tumors provides a useful research hypothesis, although a validated biomarker strategy will be necessary before clinical use can be defined.
The October 2026 data show that BeOne is generating antitumor signals across multiple investigational mechanisms, not that it has established three new treatment standards. Its progress toward pivotal trials will determine whether these signals can withstand larger patient populations, direct comparisons and the regulatory requirements necessary for commercial development.
